5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum.

Let's take a closer look at five of this past week's biggest scorchers.

Company

Oct. 5

Weekly Gain

My Watchlist

Sarepta Therapeutics (Nasdaq: SRPT  )

$34.30

121%

Add

Vringo (NYSEMKT: VRNG  )

$4.54

57%

Add

Coldwater Creek (Nasdaq: CWTR  )

$4.36

31%

Add

Primero Mining (NYSE: PPP  )

$7.37

41%

Add

Mattress Firm (Nasdaq: MFRM  )

$33.50

19%

Add

Source: Barron's.

Sarepta Therapeutics more than doubled on favorable results for its promising cystic fibrosis drug. Young biotechs are obviously risky, but investors still warm up to the opportunity after seeing big moves like this one.

Vringo shouted "Bingo!" after a federal district court judge refused a request to throw out a patent infringement suit that the company initiated against the major search engines. The trial is set to begin next week.

Coldwater Creek shares heated up after Piper Jaffray boosted its rating on the struggling retailer from neutral to overweight. Coldwater Creek also completed a reverse stock split on Thursday.

Primero Mining rose more than 41% shortly after the market open on Friday after the junior gold miner said it had received a positive ruling from Mexican tax authorities on the way it reports silver revenues.

Mattress Firm didn't slumber even after the fast-growing bedding retailer completed a secondary offering of 4.7 million shares. The bad news is that the company isn't getting any of the money since all of the shares were sold by early investors. Given the chain's acquisition-minded ways, it could have used more money as it continues to roll up a highly fragmented sector. The good news, though, is that the offering isn't dilutive.

More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, the Fool has a special report on three stocks set to dominate the world. The report is free -- like this article -- but it won't be around forever, so check it out now.

Rick Aristotle Munarriz has no positions in the stocks mentioned above. The Motley Fool owns shares of Primero Mining. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 08, 2012, at 10:26 PM, JamesFitzgerald wrote:

    Sarepta does not have a drug for Cystic Fibrosis. The drug is for Duchenne muscular dystrophy.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2048005, ~/Articles/ArticleHandler.aspx, 8/23/2014 5:34:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement